Who are OPTIVE PLUS®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GenTeal PM Night-Time, PEG- 400 based artificial tear, Rohto Dry-Aid®, Sodium Hyaluronate, sodium hyaluronate 0.18%, REFRESH LIQUIGEL®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/optive-plus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OPTIVE PLUS® — Competitive Intelligence Brief

OPTIVE PLUS® (OPTIVE PLUS®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ocular lubricant. Area: Ophthalmology.

phase 2 ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OPTIVE PLUS® (OPTIVE PLUS®) — Allergan. OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
OPTIVE PLUS® TARGET	OPTIVE PLUS®	Allergan	phase 2	ocular lubricant
GenTeal PM Night-Time	GenTeal PM Night-Time	Joseph B. Ciolino, MD	marketed	Ocular lubricant / Artificial tear
PEG- 400 based artificial tear	PEG- 400 based artificial tear	Bp Consulting, Inc	marketed	Artificial tear / Ocular lubricant
Rohto Dry-Aid®	Rohto Dry-Aid®	The Mentholatum Company	marketed	Artificial tear / ocular lubricant
Sodium Hyaluronate	Sodium Hyaluronate	Tianjin Eye Hospital	marketed	Artificial tear / ocular lubricant
sodium hyaluronate 0.18%	sodium hyaluronate 0.18%	Allergan	marketed	Artificial tear / Ocular lubricant
REFRESH LIQUIGEL®	REFRESH LIQUIGEL®	Allergan	marketed	Artificial tear / ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ocular lubricant class)

Allergan · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPTIVE PLUS® — Competitive Intelligence Brief. https://druglandscape.com/ci/optive-plus. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab